Document Type


Publication Date



This is the peer reviewed version of the following article: Huang, Y., Dinh, A., Heron, S., Gasiewski, A., Kneib, C., Mehler, H., Mignogno, M.T., Morlen, R., Slavich, L., Kentzel, E., Frackelton, E.C., Duke, J.L., Ferriola, D., Mosbruger, T., Timofeeva, O.A., Geier, S.S., & Monos, D. (2019). Assessing the utilization of high-resolution 2-field HLA typing in solid organ transplantation. American Journal of Transplantation, which has been published in final form at DOI: 10.1111/ajt.15258. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.


HLA typing in solid organ transplantation (SOT) is necessary for determining HLA-matching status between donor-recipient pairs and assessing patients' anti-HLA antibody profiles. Histocompatibility has traditionally been evaluated based on serologically defined HLA antigens. The evolution of HLA typing and antibody identification technologies, however, has revealed many limitations with using serologic equivalents for assessing compatibility in SOT. The significant improvements to HLA typing introduced by next-generation sequencing (NGS) require an assessment of the impact of this technology on SOT. We have assessed the role of high-resolution 2-field HLA typing (HR-2F) in SOT by retrospectively evaluating NGS-typed pre- and post-SOT cases. HR-2F typing was highly instructive or necessary in 41% (156/385) of the cases. Several pre- and posttransplant scenarios were identified as being better served by HR-2F typing. Five different categories are presented with specific case examples. The experience of another center (Temple University Hospital) is also included, whereby 21% of the cases required HR-2F typing by Sanger sequencing, as supported by other legacy methods, to properly address posttransplant anti-HLA antibody issues.

Table 1.docx (13 kB)
Table 2.docx (14 kB)
Table 3.docx (19 kB)
Table 4.docx (16 kB)
Table 5.docx (15 kB)

PubMed ID




Included in

Pathology Commons